Mounjaro (tirzepatide) / Eli Lilly - LARVOL DELTA

Superior Cerebrovascular Outcomes with Tirzepatide versus Semaglutide in Diabetic CABG Patients: A Global Network Study of Propensity-Matched Patients. (PubMed, Cardiovasc Drugs Ther) - "In patients with T2DM undergoing CABG, tirzepatide was associated with improved cerebrovascular and cardiovascular outcomes, reduced venous thrombotic complications, and lower long-term mortality and healthcare utilization compared to semaglutide. These findings support the therapeutic potential of dual GLP-1/GIP receptor agonism in high-risk post-CABG populations."

Journal • Acute Coronary Syndrome • Cardiovascular • CNS Disorders • Diabetes • Hematological Disorders • Infectious Disease • Metabolic Disorders • Myocardial Infarction • Thrombosis • Type 2 Diabetes Mellitus • Vascular Neurology

Eustachian Tube Disorders in Patients Prescribed Glucagon-like Peptide-1 (GLP-1) Agonists: A Propensity Score Matching Analysis (AAO-HNSF 2025) - "Analyses included all GLP-1 agonists combined and individual agents (Dulaglutide, Exenatide, Liraglutide, Lixisenatide, Semaglutide, Tirzepatide)... Different GLP-1 agonists were associated with varying risks for eustachian tube disorders. A history of GLP-1 agonist use, including the specific agent, should be considered when patients present with symptoms related to the eustachian tube."

Clinical • Diabetes • Metabolic Disorders • Otorhinolaryngology

Glucagon-Like Peptide-1 Receptor Agonist Usage in Sleep Surgery Clinic Patients (AAO-HNSF 2025) - "GLP-1 RA use in a sleep surgery clinic is higher than that of the national average. Factors associated with usage included higher BMI, OSA diagnosis, and White race. Future work should explore trends in GLP-1 RA usage as indications and insurance coverage have recently expanded to include OSA."

Clinical • Surgery • CNS Disorders • Diabetes • Genetic Disorders • Metabolic Disorders • Obesity • Obstructive Sleep Apnea • Respiratory Diseases • Sleep Disorder

Management of Early-Onset Type 2 Diabetes in Adults: Current Evidence and Future Directions. (PubMed, Diabetes Metab J) - "We provide broad recommendations for future research and clinical practice based on the current evidence. In conclusion, substantial further research is required to inform tailored, evidence-based guidelines and improve long-term outcomes in this underserved population."

Journal • Review • CNS Disorders • Depression • Diabetes • Metabolic Disorders • Psychiatry • Type 2 Diabetes Mellitus

WHO updates essential medicines list to include key...diabetes treatments (CNBC-TV18) - "The WHO also included GLP-1 receptor agonists, such as dulaglutide, semaglutide, liraglutide, and the dual GLP-1/GIP agonist tirzepatide, to treat type 2 diabetes in patients who have been diagnosed with cardiovascular disease, chronic kidney disease, or obesity (BMI ≥ 30 kilograms per square meter)."

Commercial • Chronic Kidney Disease • Obesity • Type 2 Diabetes Mellitus

Sleep and circadian effects on the incretin system. (PubMed, Curr Sleep Med Rep) - "Evidence suggests that sleep and circadian rhythms impact the incretin system, although findings are somewhat mixed due to the variety of methods employed. In light of the growing interest in new clinical applications for incretin therapies, more research is needed to fully understand the relationship between sleep, circadian rhythms, and incretin secretion."

Journal • Diabetes • Genetic Disorders • Metabolic Disorders • Obesity • Obstructive Sleep Apnea • Respiratory Diseases • Sleep Disorder

Tirzepatide (Mounjaro®) : a GIP/GLP-1 receptor dual agonist for the treatment of type 2 diabetes (PubMed, Rev Med Liege) - "Tirzepatide is a unimolecular dual agonist of both glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors, recently commercialized and reimbursed in Belgium for the treatment of type 2 diabetes (T2D). Tirzepatide is now refunded under conditions in Belgium for the treatment of TD2 in patients with a body mass index ≥ 30 kg/m² and a HbA1c level > 7.5 % with antihyperglycaemic therapy including metformin. These reimbursement conditions are similar to those of pure GLP-1 receptor agonists but are more restrictive than the indications validated by the European Medicines Agency and the latest guidelines by international scientific societies."

Journal • Review • Diabetes • Genetic Disorders • Metabolic Disorders • Type 2 Diabetes Mellitus

Effect of Glucagon-Like Peptide 1 Receptor Agonists on Patients With Rheumatoid Arthritis. (PubMed, ACR Open Rheumatol) - "This study suggests that the use of GLP-1RAs can improve RA disease activity and cardiovascular risk profile. Although further research is needed, this novel finding has significant clinical implications because it suggests that anti-obesity medications may improve both cardiovascular and RA outcomes."

Journal • Cardiovascular • Diabetes • Dyslipidemia • Genetic Disorders • Immunology • Inflammatory Arthritis • Metabolic Disorders • Obesity • Pain • Rheumatoid Arthritis • Rheumatology • CRP

Effect of Tirzepatide Treatment on Hepatic Biomarkers in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease and Type 2 Diabetes Mellitus. (PubMed, Hepatol Res) - No abstract available

Biomarker • Journal • Diabetes • Hepatology • Metabolic Disorders • Metabolic Dysfunction-Associated Steatotic Liver Disease • Type 2 Diabetes Mellitus

pH-responsive porous pollen hydrogel for oral tirzepatide delivery to improve glycaemic control and insulin sensitivity (EASD 2025) - "This study demonstrates that the pollen-based pH-responsive hydrogel system is a promising oral delivery platform for tirzepatide. It effectively protects the peptide from gastric degradation, prolongs gastrointestinal retention, and enhances bioavailability, resulting in improved glycemic control and insulin sensitivity without inducing intestinal damage. This strategy offers a non-invasive and biocompatible alternative for peptide-based diabetes therapy."

Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Mapping the global research landscape of tirzepatide: a bibliometric analysis of trends, collaborations, and emerging themes in obesity and diabetes managements. (PubMed, Naunyn Schmiedebergs Arch Pharmacol) - "Thematic evolution showed shifts toward real-world evidence and metabolic dysfunction-associated steatotic liver disease, reflecting broadening research scope. Tirzepatide research is growing globally with diverse collaborations, informing future therapeutic strategies and highlighting gaps in long-term safety, accessibility, and cost-effectiveness."

Journal • Diabetes • Genetic Disorders • Hepatology • Metabolic Disorders • Metabolic Dysfunction-Associated Steatotic Liver Disease • Obesity • Type 2 Diabetes Mellitus

Semaglutide and Tirzepatide in Patients With Heart Failure With Preserved Ejection Fraction. (PubMed, JAMA) - P | "In analyses using expanded eligibility criteria, 58 333 patients were included in the semaglutide vs sitagliptin cohort, 11 257 for tirzepatide vs sitagliptin, and 28 100 for tirzepatide vs semaglutide...Tirzepatide showed no meaningful benefit over semaglutide. ClinicalTrials.gov Identifiers: NCT06914102, NCT06914154, NCT06914141."

Journal • Cardiovascular • Congestive Heart Failure • Diabetes • Genetic Disorders • Heart Failure • Metabolic Disorders • Obesity • Type 2 Diabetes Mellitus

Holding vs. Continuing Incretin-based Therapies Before Upper Endoscopy (clinicaltrials.gov) - P4 | N=60 | Suspended | Sponsor: The Cleveland Clinic | Phase classification: P=N/A ➔ P4 | N=120 ➔ 60 | Recruiting ➔ Suspended

Enrollment change • Phase classification • Trial suspension • Diabetes • Gastrointestinal Disorder • Genetic Disorders • Metabolic Disorders • Obesity • Type 2 Diabetes Mellitus

Cardiovascular Effects and Tolerability of GLP-1 Receptor Agonists: A Systematic Review and Meta-Analysis of 99,592 patients. (PubMed, J Am Coll Cardiol) - "GLP-1 RAs reduce mortality and MACE in high-risk populations, highlighting benefits beyond glycemic control. These come at increased GI and gallbladder risks. Variation in efficacy and tolerability supports tailoring GLP-1 RA therapy to individual patient characteristics and treatment goals."

Journal • Retrospective data • Acute Kidney Injury • Cardiovascular • Congestive Heart Failure • Diabetes • Genetic Disorders • Heart Failure • Infectious Disease • Metabolic Disorders • Myocardial Infarction • Nephrology • Obesity • Oncology • Pancreatic Cancer • Pancreatitis • Renal Disease

Characterisation of Myo4 in the murine diet-induced obesity model: a first-in-class anti-obesogenic muscle-preserving small molecule metabolic modulator. (EASD 2025) - "Clinical trials such as STEP1, STEP4, and SUSTAIN8 with semaglutide showed lean mass accounted for 40% of weight loss, with similar results observed with liraglutide (SCALE), tirzepatide (SURMOUNT-1), and dulaglutide (AWARD-11)... Myo4 is a novel anti-obesogenic and muscle-preserving therapeutic, usable as monotherapy for obesity requiring weight loss with muscle preservation, or in combination with GLP-1RA to prevent loss of SkM mass/function."

Preclinical • Diabetes • Metabolic Disorders • Obesity • Type 2 Diabetes Mellitus

Medications for adults with type 2 diabetes: a living systematic review and network meta-analysis. (PubMed, BMJ) - "This living systematic review provides a comprehensive summary of the cardiovascular, kidney, and weight loss benefits, as well as medication-specific harms of medications for adults with type 2 diabetes, including effects of SGLT-2 inhibitors, GLP-1RAs, finerenone and tirzepatide."

Journal • Retrospective data • Alzheimer's Disease • Cardiovascular • Chronic Kidney Disease • CNS Disorders • Congestive Heart Failure • Dementia • Diabetes • Heart Failure • Infectious Disease • Metabolic Disorders • Musculoskeletal Diseases • Nephrology • Orthopedics • Pain • Renal Disease • Severe Hypoglycemia • Type 2 Diabetes Mellitus

Impact of GLP-1 Receptor Agonist or GIP/GLP-1 Receptor Agonist on Clinical Outcomes in Obese Patients With Inflammatory Bowel Disease: A Propensity-Matched Analysis (ACG 2025) - "Adults with IBD and obesity (BMI ≥30) were matched 1:1 based on demographics, commodities, and baseline medication use, comparing those on GLP-1RA (Semaglutide/dulaglutide/liraglutide) or GIP/GLP-1RA (Tirzepatide) to those not on these medications. The primary composite outcome included all-cause hospitalization, steroid use, colectomy, initiation of biologic (Vedolizumab, Ustekinumab, Risankizumab), and initiation of small molecules (Upadacitinib, tofacitinib) over 10 years... In the matched IBD cohort (n=5,772 per group), GLP-1RA or GIP/GLP-1RA use was associated with significantly reduced risks of primary composite outcome (51% vs. 65%, OR 0.562, CI 0.522-0.606; p< 0.001), risk of hospitalization (27% vs. 43.2%), all-cause mortality (2.8% vs.12.1%), steroid use (41.2% vs 49.9%), colectomy (0.4% vs."

Clinical • Clinical data • Crohn's disease • Gastroenterology • Gastrointestinal Disorder • Genetic Disorders • Immunology • Inflammation • Inflammatory Bowel Disease • Obesity • Pancreatitis • Ulcerative Colitis

Association of changes in taste intensity with satiety, appetite and food cravings in people with overweight and obesity treated with incretin-based therapies: a cross-sectional exploratory study (EASD 2025) - "Individuals were grouped according to the type of incretin-based therapy: 217 received semaglutide (Wegovy, Novo Nordisk, Denmark; baseline median [IQR] BMI 35.9 kg/m² [33.3; 38.2]), 148 semaglutide (Ozempic, Novo Nordisk, Denmark; BMI 34.7 kg/m² [33.5; 36.5]) and 46 tirzepatide (Mounjaro, Eli Lilly, USA; BMI 36.2 kg/m² [34.3; 37.1]) (p=0.216 for BMI). In addition to the similar rates of body weight reduction observed among the incretin-based therapy groups, self-reported changes in taste perception were also comparable across groups. These changes during incretin-based therapy were associated with favourable appetite-related outcomes, suggesting a potential mechanism contributing to treatment response."

Diabetes • Metabolic Disorders • Obesity • Type 2 Diabetes Mellitus

Tirzepatide as an adjunctive therapy in type 1 diabetes: real-world experience from a large UK centre (EASD 2025) - "Obesity is prevalent in people with type 1 diabetes (T1D), exacerbating insulin resistance, thereby augmenting cardiometabolic risk... In real-world use in people with T1D, tirzepatide was safe and generally well tolerated, with significant clinical benefits including weight loss, reduced insulin requirements, and improvement of glycaemic metrics, without increasing hypoglycaemia. Definitive data from RCTs in T1D are required to confirm these findings."

Clinical • Real-world • Real-world evidence • Diabetes • Hypoglycemia • Metabolic Disorders • Obesity • Pancreatitis • Type 1 Diabetes Mellitus • Type 2 Diabetes Mellitus

Influence of Type 2 Diabetes on the Effects of Tirzepatide in Patients With Heart Failure and a Preserved Ejection Fraction With Obesity: A Prespecified Stratification-Based Analysis. (PubMed, J Am Coll Cardiol) - P3 | "Despite less pronounced weight loss, patients with HFpEF, obesity, and type 2 diabetes responded favorably to tirzepatide. This favorable response was reflected by a reduced risk of adverse heart failure outcomes and improved health status, quality of life, and functional capacity, as well as a decrease in left ventricular mass and paracardiac fat, to a degree that was similar to that in patients without diabetes. These observations raise the possibility that the heart failure benefits of incretin-based drugs may not be faithfully estimated by measuring the magnitude of the change in body weight. (SUMMIT [A Study of Tirzepatide (LY3298176) in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF) and Obesity]; NCT04847557)."

Clinical • Journal • Cardiomyopathy • Cardiovascular • Congestive Heart Failure • Diabetes • Genetic Disorders • Heart Failure • Metabolic Disorders • Obesity • Type 2 Diabetes Mellitus

Tirzepatide accelerates diabetes onset in NOD mouse model of type 1 diabetes (EASD 2025) - "Tirzepatide (TZP) is a GLP-1/GIP receptor agonist approved for the treatment of type 2 diabetes and obesity... Despite enhancing glucose clearance, TZP suppressed insulin secretion and was associated with earlier onset of diabetes in the NOD mice. These findings highlight the complexity of incretin-based therapies in T1D and show the necessity for mechanistic studies to delineate their impact on β-cell integrity."

Late-breaking abstract • Preclinical • Diabetes • Metabolic Disorders • Obesity • Type 1 Diabetes Mellitus • Type 2 Diabetes Mellitus

Multi-organ magnetic resonance-based imaging can predict health benefit from anti-obesity pharmacotherapy (EASD 2025) - "In a large-scale prospective study, multi-organ MR-based imaging improved risk stratification for cardiometabolic disease in people with obesity. Personalised risk stratification with MR imaging could target treatments to patients most likely to benefit, thus producing the most effective and cost-effective care to the greatest overall public health benefit."

Late-breaking abstract • Diabetes • Metabolic Disorders • Metabolic Dysfunction-Associated Steatohepatitis • Obesity • Type 2 Diabetes Mellitus

Semaglutide-induced Wernicke encephalopathy: a comprehensive analysis. (PubMed, Eur J Clin Nutr) - "Although GLP-1 receptors analogues (RAs) benefits-risks profile has been largely documented in diabetes, higher dosages recently approved in obesity still require further assessment...Disproportionality analysis in VigiBase showed that Wernicke encephalopathy was disproportionately reported with semaglutide, tirzepatide and the whole GLP-1RAs group. Altogether, this comprehensive analysis supports a safety signal regarding the risk of Wernicke encephalopathy with GLP-1RAs, which requires a prompt assessment, accounting for the growing use of these drugs."

Journal • CNS Disorders • Diabetes • Genetic Disorders • Metabolic Disorders • Obesity

Semaglutide or Tirzepatide and Optic Nerve and Visual Pathway Disorders in Type 2 Diabetes. (PubMed, JAMA Netw Open) - "Semaglutide and tirzepatide, the new generation of glucagon-like peptide-1 receptor agonist used to treat type 2 diabetes and obesity, were recently reported to be associated with increased risk of nonarteritic anterior ischemic optic neuropathy (NAION)...Prescription of semaglutide or tirzepatide vs other antidiabetic medications (insulins, metformin, dipeptidyl-peptidase-4 inhibitors, sodium-glucose cotransporter-2 inhibitors, sulfonylureas, thiazolidinediones, and other glucagon-like peptide 1 receptor agonists)...In this study of patients with type 2 diabetes who had no prior eye disorders, patients prescribed semaglutide or tirzepatide had an increased risk of NAION and other optic nerve disorders, although the overall risk was low. These findings highlight the need for close monitoring of these conditions."

Journal • Diabetes • Genetic Disorders • Metabolic Disorders • Obesity • Ocular Inflammation • Ophthalmology • Optic Neuritis • Pain • Type 2 Diabetes Mellitus

A Gut Reaction: Duodenal Vasculitis Unveiled After Mounjaro Use (ACG 2025) - "Introduction: Tirzepatide (Mounjaro) and other GLP-1 receptor agonists are widely used to treat type 2 diabetes and obesity; however, their potential effects on drug metabolism and immune regulation remain important areas of ongoing investigation...He was treated with IV steroids (solumedrol 40 mg TID), with symptom improvement, and discharged on an oral steroid taper...As GLP-1 receptor agonists become more commonly used for weight management, clinicians should remain vigilant for potential side effects. Upcoming prospective research, along with ongoing adverse event monitoring and post-marketing data collection, will play a vital role to better understand the immunomodulatory properties of tirzepatide and if vasculitis occurs more frequently as a side effect than is presently understood.Figure: Figure 1"

Alopecia • Bullous Pemphigoid • Cardiovascular • Dermatology • Dermatopathology • Diabetes • Gastrointestinal Disorder • Genetic Disorders • Hypertension • Immunology • Infectious Disease • Inflammation • Metabolic Disorders • Obesity • Rheumatology • Type 2 Diabetes Mellitus • Urticaria • Vasculitis